The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

@article{Vollenweider2010TheNO,
  title={The neurobiology of psychedelic drugs: implications for the treatment of mood disorders},
  author={Franz X. Vollenweider and Michael W Kometer},
  journal={Nature Reviews Neuroscience},
  year={2010},
  volume={11},
  pages={642-651}
}
After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and… 

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

State-of-the art studies have recently begun to close important knowledge gaps by elucidating the mechanisms of action of psychedelics with regard to their effects on receptor subsystems, systems-level brain activity and connectivity, and cognitive and emotional processing.

Classic Psychedelic Drugs: Update on Biological Mechanisms

Renewed interest in the effects of psychedelics in the treatment of psychiatric disorders warrants a better understanding of the neurobiological mechanisms underlying the effects of these substances.

A potential role for psilocybin in the treatment of obsessive-compulsive disorder

  • E. Jacobs
  • Psychology, Biology
    Journal of Psychedelic Studies
  • 2020
Although the current evidence is limited, that multiple signals point in directions consistent with treatment potential, alongside the psychological and physiological safety of clinically administered psilocybin, support the expansion of research, both in animal models and in further randomized controlled trials, to properly investigate this potential.

Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics.

Animal models of serotonergic psychedelics.

The behavioral effects induced by psychedelic drugs in rodent models are reviewed, the translational potential of these findings are discussed, and areas where further research is needed to better understand the molecular mechanisms and neuronal circuits underlying their neuropsychological effects are defined.

Molecular targets of psychedelic‐induced plasticity

Some of the most recent findings in human studies are discussed and contextualize them considering previous preclinical models studying phenomena related to synaptic plasticity, with a special emphasis on knowledge gaps, challenges, and the limitations to evaluate the underpinnings of psychedelics' potential antidepressant action.

Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine

The pharmacology of hallucinogenic compounds is summarized by underscoring the differences between psychedelic and nonpsychedelic hallucinogens as well as entactogens, and their behavioral effects in both animals and humans are described.

Apotential role for psilocybin in the treatment of obsessive-compulsive disorder

Although the current evidence is limited, that multiple signals point in directions consistent with treatment potential, alongside the psychological and physiological safety of clinically administered psilocybin, support the expansion of research, both in animal models and in further randomized controlled trials, to properly investigate this potential.

Psychedelic drugs for psychiatric disorders

...

References

SHOWING 1-10 OF 171 REFERENCES

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

There is growing evidence that the glutamatergic system is central to the neurobiology and treatment of mood disorders and exciting new prospects for the development of improved therapeutics for these devastating disorders are discussed.

Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.

Serotonin research: contributions to understanding psychoses.

The experimental use of psychedelic (LSD) psychotherapy.

The history of research with psychedelic drugs has produced a variety of methods for their use and conflicting claims about results. First came the wave of excitement among experimentalists in the

Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.

The data demonstrate that the neuronal substrate of normal and abnormal thought and behavior is associated with a distributed neuronal network and with multiple interactive neurotransmitter systems, and support the view that the hallucinogen challenge paradigm constitutes a powerful tool for elucidating the pathophysiology of neuropsychiatric disorders.

Neurocognitive mechanisms in depression: implications for treatment.

Cognitive, neuroanatomical, and pharmacological tiers of research are drawn together to identify treatment targets and directions for future investigation to identify people at risk, minimize relapse, and maximize long-term beneficial outcomes for those suffering from depression.

Antidepressant effects of ketamine in depressed patients

Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action

In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the serotonin-2A antagonist ketanserin or the atypical antipsychotics risperidone, but were increased by the dopamine antagonist and typical antipsychotic haloperidol.

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.

Group II metabotropic glutamate receptors were targeted to normalize glutamatergic disruptions associated with an animal model of schizophrenia, the phencyclidine model, and an agonist of this group of receptors attenuated the disruptive effects of Phencyclidine on working memory, stereotypy, locomotion, and cortical glutamate efflux.

Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?

  • C. Large
  • Psychology, Medicine
    Journal of psychopharmacology
  • 2007
The extent to which the different hypotheses that have been proposed to account for the psychotomimetic effects of NMDA receptor antagonist have been validated by the results of these trials is considered.
...